VBI Vaccines (NASDAQ:VBIV) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a report released on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

VBI Vaccines Stock Performance

Shares of NASDAQ:VBIV opened at $0.61 on Thursday. The firm has a market cap of $14.43 million, a PE ratio of -0.05 and a beta of 1.93. The firm’s 50 day simple moving average is $0.61 and its 200-day simple moving average is $0.61. VBI Vaccines has a one year low of $0.45 and a one year high of $3.86.

Hedge Funds Weigh In On VBI Vaccines

Several institutional investors have recently bought and sold shares of the business. Engineers Gate Manager LP purchased a new position in VBI Vaccines during the first quarter valued at approximately $26,000. Alliancebernstein L.P. increased its holdings in VBI Vaccines by 9.9% during the third quarter. Alliancebernstein L.P. now owns 188,900 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 17,000 shares during the period. Raymond James Financial Services Advisors Inc. increased its holdings in VBI Vaccines by 8.8% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 267,148 shares of the biopharmaceutical company’s stock valued at $443,000 after buying an additional 21,587 shares during the period. Voya Investment Management LLC increased its holdings in VBI Vaccines by 29.7% during the fourth quarter. Voya Investment Management LLC now owns 95,428 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 21,824 shares during the period. Finally, Oppenheimer & Co. Inc. increased its holdings in VBI Vaccines by 38.5% during the first quarter. Oppenheimer & Co. Inc. now owns 100,400 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 27,900 shares during the period. 12.26% of the stock is owned by hedge funds and other institutional investors.

VBI Vaccines Company Profile

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.